Merck (MRK) Will Present Phase 2 Data from Two HCV Treatments at EASL

March 24, 2014 7:31 AM EDT Send to a Friend
Merck (NYSE: MRK) announced that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments - MK-5172 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login